One BLA, Multiple Variants: FDA Proposes a Path for Personalized Gene Editing

The FDA, on October 27, announced a draft guidance, “Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management,” proposes a framework for including multiple variants of an individualized genome-editing product in one Biologics License Application (BLA). It also explains how developers could add variants after approval. The guidance remains a draft, with nonbinding recommendations. 

The draft guidance addresses individualized genome-editing treatments for diseases caused by known mutations in a single gene, with product variants designed to achieve the same editing outcome. For example, related versions of a treatment could address different mutations while restoring the same gene’s normal function. It does not broadly permit unrelated gene therapies to share one application.  

Central to the approach is the Individualized Feature Space (IFS): predefined boundaries describing which components of a treatment may vary. A developer might specify allowable changes to the guide RNA that directs editing to a patient’s mutation. Within those boundaries, a qualifying new variant would be treated as a manufacturing change rather than a separate product. 

Reporting on FDA’s explanatory webinar, Regulatory Focus described the proposal as addressing a gap between individualized therapy development and commercial approval. FDA officials encouraged developers to establish their proposed IFS during clinical development, supported by a scientific rationale and appropriate evidence.  

Several features are especially consequential: 

• Evidence could support additional variants. After initial approval, developers could use existing clinical evidence and laboratory testing to support new variants within the established boundaries, without conducting a new clinical trial for each one when the evidence supports that approach. 

• Safety testing remains variant-specific. Developers would assess unintended editing risks for each guide RNA/editor combination. Manufacturing controls must reliably accommodate the permitted variation. 

• Expansion requires additional review. Widening the IFS requires a prior approval supplement. Changes that fundamentally alter the product or introduce significant new risks may require a new BLA. 

• Planning can begin before approval. FDA recommends an agreed postapproval change-management protocol describing anticipated changes, testing and reporting procedures.  

The potential commercial implications are substantial. A shared application and reusable evidence could reduce repetitive work and improve the economics of serving very small patient groups.  

BioPharma Dive reported that analysts viewed the proposal as enabling greater “plug and play” flexibility, while Beam Therapeutics CEO John Evans welcomed its alignment with base-editing science. 

For patients, the potential benefit is broader access to treatments matched to their mutations. For developers and investors, clearer rules could make platform investments easier to evaluate. For manufacturers and testing providers, the approach could increase demand for flexible production and reliable assays across related variants.